Published in Biologics on August 17, 2012
BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS One (2013) 0.90
BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS One (2013) 0.86
Human Prostate Cancer Hallmarks Map. Sci Rep (2016) 0.75
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12.55
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature (1999) 8.42
The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal (2002) 6.35
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med (2002) 5.25
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Recent insights into the role of Notch signaling in tumorigenesis. Blood (2005) 3.37
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Rational targeting of Notch signaling in cancer. Oncogene (2008) 3.02
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One (2010) 2.63
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res (2004) 2.15
NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets (2006) 2.14
Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . Prostate (2000) 2.03
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem (2010) 1.93
Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res (2001) 1.92
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res (2000) 1.86
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate (1999) 1.71
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res (2009) 1.66
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets (2009) 1.66
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res (2007) 1.66
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res (2009) 1.57
The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am (1999) 1.55
Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol (2005) 1.54
Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.49
The Notch pathway in prostate development and cancer. Differentiation (2008) 1.49
Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 1.42
Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg (1991) 1.36
The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol (2012) 1.29
LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res (2005) 1.28
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer (2007) 1.23
Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab (2003) 1.13
Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res (2004) 1.09
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol (2010) 1.06
Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J Mol Med (Berl) (2011) 1.05
PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J Pathol (2011) 1.05
A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther (2005) 1.04
Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol (2011) 1.00
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate (2011) 0.97
Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem (2009) 0.97
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int (2009) 0.94
Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. Gene Ther (2006) 0.94
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol (2012) 0.93
Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res (2011) 0.92
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis (2012) 0.92
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology (2007) 0.91
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol (2012) 0.90
Notch activation by phenethyl isothiocyanate attenuates its inhibitory effect on prostate cancer cell migration. PLoS One (2011) 0.90
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther (2009) 0.89
New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opin Investig Drugs (2010) 0.89
Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling. J Nutr Biochem (2011) 0.89
Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp Oncol (2009) 0.88
GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther (2007) 0.88
HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia (2009) 0.87
Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. J Immunother (2011) 0.84
Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs (2011) 0.84
Immunotherapy for advanced prostate cancer. Rev Urol (2007) 0.83
Wortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of IAP-2 protein. Exp Oncol (2005) 0.83
Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathol Oncol Res (2011) 0.83
A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer. Urology (2012) 0.82
Chrysanthemum indicum L. extract induces apoptosis through suppression of constitutive STAT3 activation in human prostate cancer DU145 cells. Phytother Res (2012) 0.81
Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) (2012) 0.81
Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore. Ann Acad Med Singapore (2007) 0.81
Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol (2012) 0.81
New approaches to target the androgen receptor and STAT3 for prostate cancer treatments. Mini Rev Med Chem (2009) 0.79
Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer. Ann Pharmacother (2010) 0.76
The usefulness of phosphorylated-signal transduction and activators of transcription 3 in detecting prostate cancer from negative biopsies. Eur J Surg Oncol (2012) 0.76
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy. Front Oncol (2012) 0.76
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
PSA screening among elderly men with limited life expectancies. JAMA (2006) 5.70
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res (2006) 3.17
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev (2002) 2.46
Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells (2012) 1.94
Recurrence of high-risk bladder cancer: a population-based analysis. Cancer (2013) 1.87
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
Quality of care in patients with bladder cancer: a case report? Cancer (2011) 1.73
Specific targeting of Wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis (2010) 1.67
Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer (2005) 1.63
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2007) 1.58
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res (2009) 1.57
Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer (2011) 1.55
Cutaneous metastases from transitional cell carcinoma of the bladder. Urology (2006) 1.50
Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology (2005) 1.47
Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology (2006) 1.46
Factors associated with reduction in use of neoadjuvant androgen suppression therapy before radical prostatectomy. Urology (2013) 1.44
Cavernous nerve repair with allogenic adipose matrix and autologous adipose-derived stem cells. Urology (2011) 1.43
Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs. Urology (2005) 1.41
Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. Urology (2011) 1.39
S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev (2012) 1.33
Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol (2007) 1.29
Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. J Urol (2007) 1.27
The impact of marriage on bladder cancer mortality. Urol Oncol (2008) 1.23
A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. Cancer Res (2008) 1.15
The impact of provider volume on outcomes from urological cancer therapy. J Urol (2005) 1.11
Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int (2011) 1.10
Quality of life in long-term survivors of bladder cancer. Cancer (2006) 1.09
Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome? BJU Int (2006) 1.09
Prostate cancer screening parameters in a high-risk African-Caribbean population. Urology (2004) 1.08
Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int (2009) 1.07
Retracted Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res (2004) 1.06
Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. J Urol (2007) 1.06
Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer Prev Res (Phila) (2010) 1.05
Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture. Cancer (2011) 1.04
The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol (2006) 1.03
Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer (2009) 1.03
Beneficial effects of tea and its polyphenols against prostate cancer. Mol Nutr Food Res (2006) 1.02
Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sci (2010) 1.02
Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res (2009) 1.02
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Use of bipolar power source for transurethral resection of bladder tumor in patient with implanted pacemaker. Urology (2005) 1.01
The prevalence of renal cell carcinoma diagnosed at autopsy. BJU Int (2005) 1.00
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int (2008) 1.00
Squamous cell carcinoma of the penis: evaluation of data from the surveillance, epidemiology, and end results program. Cancer (2004) 0.99
The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. BJU Int (2015) 0.97
Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nat Clin Pract Urol (2008) 0.96
Candidate quality of care indicators for localized bladder cancer. Urol Oncol (2009) 0.96
Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol (2009) 0.94
Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One (2013) 0.94
Spaghetti wrist: management and outcome. J Coll Physicians Surg Pak (2004) 0.94
Effect of meeting Leapfrog volume thresholds on complication rates following complex surgical procedures. Ann Surg (2010) 0.94
Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat (2005) 0.93
The example of CaPSURE: lessons learned from a national disease registry. World J Urol (2011) 0.92
Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res (2011) 0.92
Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology (2003) 0.91
The S100A4 Oncoprotein Promotes Prostate Tumorigenesis in a Transgenic Mouse Model: Regulating NFκB through the RAGE Receptor. Genes Cancer (2013) 0.91
BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS One (2013) 0.90
Health related quality of life assessments for patients with bladder cancer. J Urol (2004) 0.90
Chemopreventive effect of Vitis vinifera extract on 12-O-tetradecanoyl-13-phorbol acetate-induced cutaneous oxidative stress and tumor promotion in murine skin. Pharmacol Res (2002) 0.88
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion markers in CD-1 mouse skin by oleandrin. Toxicol Appl Pharmacol (2004) 0.88
Prevalence of prostate specific antigen testing for prostate cancer in elderly men. J Urol (2006) 0.88
Evidence-based medicine in urology. World J Urol (2011) 0.88
Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. Int J Cancer (2012) 0.88
The future of clinical practice guidelines in urology. Eur Urol (2011) 0.87
Specificity of procedure volume and in-hospital mortality association. Ann Surg (2007) 0.87
Estimating postoperative mortality and morbidity risk of radical cystectomy with continent diversion using predictor equations. J Urol (2009) 0.86
BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS One (2013) 0.86
Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med (2009) 0.86
Intensity modulated radiation therapy replaces 3-dimensional conformal radiotherapy as prostate cancer treatment. J Urol (2012) 0.85
Retraction: Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res (2013) 0.85
Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer. Rev Urol (2006) 0.84
Tea beverage in chemoprevention and chemotherapy of prostate cancer. Acta Pharmacol Sin (2007) 0.84
The connection between selective referrals for radical cystectomy and radical prostatectomy and volume-outcome effects: an instrumental variables analysis. Am J Med Qual (2011) 0.84
In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J Nucl Med (2009) 0.84
Wound infiltration with Bupivacaine versus Ketorolac for postoperative pain relief in minor to moderate surgeries. J Pak Med Assoc (2009) 0.84
Fluorescence cystoscopy and bladder surveillance. Curr Opin Urol (2004) 0.84
Bias due to missing SEER data in D'Amico risk stratification of prostate cancer. J Urol (2012) 0.83
Urinary markers/cytology: what and when should a urologist use. Urol Clin North Am (2013) 0.83
Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol (2012) 0.81
Characteristics of patients and predictors of in-hospital mortality after hospitalization for head and neck cancers. Cancer (2006) 0.81
Adverse effect of organophosphate compounds, dichlorvos and chlorpyrifos in the reproductive tissues of transgenic Drosophila melanogaster: 70kDa heat shock protein as a marker of cellular damage. Toxicology (2007) 0.81
Suppression of thymic lymphomas and increased nonthymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene. Int J Cancer (2004) 0.81
Effect of postcystectomy infectious complications on cost, length of stay, and mortality. Urology (2009) 0.81
ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models. Int J Cancer (2014) 0.81
18F-FDG PET/CT of transitional cell carcinoma. AJR Am J Roentgenol (2009) 0.80
UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. Int Braz J Urol (2009) 0.80
Lupeol, a triterpene, prevents free radical mediated macromolecular damage and alleviates benzoyl peroxide induced biochemical alterations in murine skin. Indian J Exp Biol (2003) 0.79
Complete response of bony metastatic bladder urothelial cancer to neoadjuvant chemotherapy and cystectomy. Urol Oncol (2006) 0.79
Should men over the age of 65 years receive PSA screening? Argument in favor. Nat Clin Pract Urol (2008) 0.79